Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Enlivex Therapeutics Ltd. (1BT.F)

0.7950
+0.0150
+(1.92%)
As of 8:02:51 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 1BT.F

Recent News: 1BT.F

View More
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
GlobeNewswire yesterday
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial
Clinical Trials Arena 2 days ago
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
GlobeNewswire 3 days ago
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?
Simply Wall St. 17 days ago
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
GlobeNewswire 21 days ago
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
GlobeNewswire last month
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
GlobeNewswire last month
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
GlobeNewswire last month
Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Issues Urgent Statement on Fraudulent News Dissemination
GlobeNewswire 2 months ago
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis

RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis
ACCESS Newswire 2 months ago
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESS Newswire 3 months ago
View More

Related Tickers

PYPD PolyPid Ltd.
2.6700
-2.91%
 
BCDA BioCardia, Inc.
1.8300
-1.61%
 
CELU Celularity Inc.
1.6850
+4.66%
 
ALZN Alzamend Neuro, Inc.
0.6799
-0.76%
 
CVKD Cadrenal Therapeutics, Inc.
17.20
+1.90%
 
BCLI Brainstorm Cell Therapeutics Inc.
0.9045
+4.07%
 
LGVN Longeveron Inc.
1.6500
+2.50%
 
BSEM BioStem Technologies, Inc.
13.91
+18.89%
 
LXEO Lexeo Therapeutics, Inc.
3.4800
+3.27%
 
VIR Vir Biotechnology, Inc.
6.14
+2.85%